• Intas Biopharmaceuticals Ltd., of Ahmedabad, India, launched Mabtas in India. The product is a biosimilar version of Rituximab (Roche AG and Biogen Idec Inc.) indicated in the treatment of diseases characterized by excessive numbers of B cells, overactive B cells or dysfunctional B cells, such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis.
Read More
SAN FRANCISCO – When AiCuris GmbH, of Wuppertal, Germany, analyzed the market for human cytomegalovirus (HCMV) therapies, it found a market with high medical need, neglected by big pharma, featuring a variety of disease manifestations.
Read More
Less than a year after licensing constipation drug elobixibat from Swedish biotech Albireo AB, Ferring Pharmaceuticals SA initiated enrollment in two Phase III trials of the investigational compound in chronic idiopathic constipation (CIC).
Read More
LONDON – Redx Pharma Ltd. has unveiled a shift in strategy away from a sole focus on internally generated compounds, with the in-licensing of an early stage oncology program from Canadian biotech Pharmascience Inc.
Read More
GlaxoSmithKline plc's initiative on data transparency took a decisive step forward Tuesday as the company switched on the website that will act as the point of access to its vast repositories of clinical data and named the independent review panel who will control that access.
Read More
LONDON – The future development of a new class of antidepressants has edged closer, with the discovery of a molecular pathway that is fundamental to the development of depression. Read More
LONDON – Symphogen A/S has taken in a further €41 million (US$54.1 million) as an extension to an earlier €100 million round agreed in 2011, bringing the total raised to $185 million.
Read More